← Back to news
NewsBIOORGANIC & MEDICINAL CHEMISTRY LETTERSWednesday, December 31, 2025 · December 31, 2025

Discovery of novel imidazo[4,5-b]pyridine derivatives as noncovalent reversible Bruton's tyrosine kinase inhibitors.

WHY IT MATTERS

Recent peer-reviewed research on B-cell chronic lymphocytic leukemia that may be relevant for patients and caregivers.

Bruton's tyrosine kinase (BTK) has emerged as a validated therapeutic target for B-cell malignancies and autoimmune disorders, and covalent BTK inhibitors have demonstrated remarkable clinical efficacy. However, because of concerns regarding their off-target effects and safety profiles, there is res...

Read on PubMed
Read the original at Bioorganic & medicinal chemistry letters
ResearchPubMedB-cell chronic lymphocytic leukemiaProtein Kinase InhibitorsAgammaglobulinaemia Tyrosine Kinase

Related conditions

B-cell chronic lymphocytic leukemia

Related news

Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.